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Abstract 
A great heterogeneity of skin manifestations has been increas-
ingly associated with SARS-CoV2 infection, and especially exan-
thematous eruptions are considered among early presenting signs
in symptomatic patients. In this report, a 58-year-old patient pre-
sented with fever, generalized rash and systemic symptoms as
urgent consultation to the Dermatology Clinic of Cagliari amidst
the Italian outbreak in late March 2020. After a negative nasopha-
ryngeal swab for SARS-CoV-2, secondary syphilis was confirmed
by serological tests and skin biopsy, underlining that, even during
a global pandemic, other common and important diseases should
not be overlooked. The case also suggests thought on the ineffec-
tiveness of distancing and social containment measures when
dealing with sexually transmitted diseases. 
Introduction
On 11th March 2020, the World Health Organization (WHO)
declared coronavirus 2019 disease (COVID-19) a pandemic.1 In
addition to the most common clinical features of COVID-19,
which include fever, myalgia, cough, shortness of breath, ageusia,
anosmia and conjunctival congestion,2 skin symptoms can occur
in up to 20.4% of patients.3
A challenging aspect of such skin eruptions associated with
COVID-19 is the great heterogeneity, that challenges a broad
spectrum of differential diagnoses.4 As the dermatologic signs
may precede the respiratory symptoms or manifest themselves in
the absence of any pulmonary manifestations, it is important to
consider COVID-19 infection in case of any exanthematous erup-
tions to minimize the risk of spreading by pauci-symptomatic
individuals in an endemic area. On the contrary, fear should not
deter us from recognizing common disorders.
Case Report
In late March 2020, amidst the COVID-19 outbreak, a 58-
year-old Caucasian man affected by insulin-treated type 2 diabetes
referred to the Dermatology Clinic under the suspicion of SARS-
CoV-2 infection for a generalized, mildly pruritic exanthematous
rash associated with systemic symptoms of 2-week duration. He
had been treated by the general practitioner with paracetamol and
systemic steroids with some improvement, followed by relapse of
symptoms and worsening of the skin eruption. He denied recent
travels to the high-prevalence areas for SARS-CoV-2 infection. 
On physical examination, the patient presented with a wide-
spread erythematous morbilliform rash, slightly papular and scaly
at closer view on the trunk and radix of the limbs (Figures 1 and
2), more erythematous edematous on the face, with bilateral con-
junctival erythema (Figure 2), associated with fever (37.9°C),
cough, rhinitis, pharyngodynia, occipital headache, diffuse lym-
phadenopathy and symmetrical migratory arthritis. Isolated
papules were present on the soles while palmar regions were
spared. After inquiring the patient, he referred also a genital rash,
which spontaneously resolved, two months earlier.
Laboratory exams, including full blood count, coagulation
tests, hepatic and renal function, HIV test were normal, except for
a mild increase of ERS and C-reactive protein. Serum protein
electrophoresis showed an increased gamma peak.
Nasopharyngeal swab for SARS-CoV-2 was negative. The oph-
thalmologic consultation diagnosed a pan-uveitis. 
Histopathology of a skin biopsy showed a mild interface der-
matitis, with superficial and deep dermal perivascular and peri-
adnexal inflammatory infiltrate, whose multinucleated histiocytes
formed several noncaseating granulomas in a background of lym-
phocytic infiltrate, rich in plasma cells (Figure 3). A positive
Treponema pallidum hemagglutination (TPHA) test (>1:5120) as
well as a rapid plasma reagin test (RPR 1: 64) confirmed the diag-
nosis of secondary syphilis. The patient was treated with penicillin
G benzathine 2,400,000 UI intramuscularly weekly for 3 weeks
with rapid improvement of systemic symptoms and complete res-
olution of the skin rash. 
Significance for public health
Even during a pandemic, despite community containment and social distancing, sexually transmitted diseases persist, and syphilis should never be forgotten.
As highlighted by present report, the potential impact on public health is substantial, considering that secondary syphilis is a highly contagious generalized bac-
teremic phase of the disease. Resurgence of syphilis is an ongoing unsolved problem for at least a decade, which takes a back seat to the current dramatic
COVID-19 spreading. However, limitation to outpatients’ visits and hospital screening services due to the lockdown measures are likely to favor syphilis circu-
lation, delay diagnosis and adequate treatment. Dermatologists are in the leading position to support the medical community in such difficult situations, keep-
ing focused on good clinical practice to promptly recognize subtle but potentially severe diseases like syphilis.
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The patient was tested negative for additional STD and at the
trimestral follow up, RPR antibody titer had decreased (1:8), while
TPHA test remained stable (1:5120). 
Discussion
The reported prevalence of cutaneous signs associated with
COVID-19 pandemic is variable, ranging from the 0.2% of a
cohort of 1099 Chinese patients, to the 20.4% in a cross-sectional
Italian study.2,3 Exanthematous eruptions are considered the most
common, although less specific COVID-19 related skin manifesta-
tions, reported in about 47% of cases.4 The morphology is very
polymorphic, and classification is limited by the subjectivity of the
different reports’ description,5,6 going from widespread erythema
to urticarial, varicella-like/vesicular, purpuric, maculopapular,
morbilliform and papulo-squamous presentation. In the American
registry, 22% of the patients with laboratory-confirmed COVID-19
infection presented with a morbilliform rash, while another 9%
with a papulo-squamous eruption, occurring mostly on the trunk
and associated with mild itching.7 It is therefore not surprising that
the occurrence of a generalized morbilliform papular rash associ-
ated with cough and arthritis among the others,8 during the most
critical moment of the outbreak led to consider first a COVID-19
related manifestation. Of course, a closer observation recognized
that all skin and systemic symptoms in our patient were typical of
secondary syphilis, but one must also consider that admitting a per-
son potentially affected with COVID-19 to hospital triggers a
series of containment measures, and careful assessment should be
performed.9
More-over, social distancing and strict preventive measures
during the lockdown are supposed to affect also the circulation of
other infective diseases, such as syphilis. A decrease in STI diag-
noses, particularly of early syphilis have been reported in Italy dur-
ing the period of lockdown.10,11 Our experience suggests not to let
the guard down.  Despite the global health emergency and the fear
of non-recognizing COVID-19, other common diseases should not
to be disregarded in everyday clinical practice. This is particularly
true for a disease like secondary syphilis which can cause a wide
range of symptoms, as the nickname of “great masquerader” points
out, similar to actual COVID-19 manifestations.
Conclusion
Current pandemic is adsorbing most of the resources of our
healthcare system, and specialty outpatients’ services, as well as
Hospital Units not directly involved in critically ill COVID-19
patients’ risk to be overshadowed. A false sense of protection and
social containment generated by lockdown measures can lead to
underestimating sexually transmitted diseases circulation in the
community. Especially syphilis diagnosis requires an expert eye,
and a high level of suspicion, as it is characteristic of the dermatol-
ogy on-field practice.
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Figure 1. Widespread erythematous morbilliform rash on the
trunk and radix of limbs.
Figure 2. Closer view of the slightly papular and scaly surface of
the eruption on the abdomen. A more erythematous edematous
component was present on the face, with bilateral conjunctival
erythema. 
Figure 3. Histopathology from skin biopsy: mild interface der-
matitis, with superficial and deep dermal perivascular and peri-
adnexal inflammatory infiltrate with several multinucleated histi-
ocytes (Hematoxylin & Eosin stain, magnification 10X). On the
right, particular of dermal noncaseating granulomas in a back-
ground of lymphocytic infiltrate, rich in plasma cells (inset).
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